ArticleOncogene2007
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Article in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 122 citations in OpenAlex.
- Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- Disruption of CTCF binding by germline non-coding variants inmedRxiv : the preprint server for health sciences · 2026Article
- A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility.Research square · 2026Article
- MEK5/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing Cyclin D/CDK4-mediated G1/S progression.Cell death & disease · 2025Article
- Review
- Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers-An Overview.Gels (Basel, Switzerland) · 2022Review
- The dosimetric enhancement of GRID profiles using an external collimator in pencil beam scanning proton therapy.Medical physics · 2022Article
- Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis.Nature communications · 2022Article
- Signal pathways of melanoma and targeted therapy.Signal transduction and targeted therapy · 2021Review
- Identification of robust reference genes for studies of gene expression in FFPE melanoma samples and melanoma cell lines.Melanoma research · 2020Article
- High-Resolution Copy Number Patterns From Clinically Relevant FFPE Material.Scientific reports · 2019Article
- NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.Molecular oncology · 2017Article
- TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle.Oncogene · 2016Article
- Copy number variation in archival melanoma biopsies versus benign melanocytic lesions.Cancer biomarkers : section A of Disease markers · 2016Article
- Variations of BRAF mutant allele percentage in melanomas.BMC cancer · 2015Article
- Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.The Journal of investigative dermatology · 2015Article
- KIT is a frequent target for epigenetic silencing in cutaneous melanoma.The Journal of investigative dermatology · 2015Article
- The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3.The Journal of biological chemistry · 2014Article
- Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Mechanisms of chromosomal instability in melanoma.Environmental and molecular mutagenesis · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant melanoma is an aggressive, heterogeneous disease where new biomarkers for diagnosis and clinical outcome are needed. We searched for chromosomal aberrations that characterize its pathogenesis using 47 different melanoma cell lines and tiling-resolution bacterial artificial chromosome-arrays for comparative genomic hybridization. Major melanoma genes, including BRAF, NRAS, CDKN2A, TP53, CTNNB1, CDK4 and PTEN, were examined for mutations. Distinct copy number alterations were detected, including loss or gain of whole chromosomes but also minute amplifications and homozygous deletions. Most common overlapping regions with losses were mapped to 9p24.3-q13, 10 and 11q14.1-qter, whereas copy number gains were most frequent on chromosomes 1q, 7, 17q and 20q. Amplifications were delineated to oncogenes such as MITF (3p14), CCND1 (11q13), MDM2 (12q15), CCNE1 (19q12) and NOTCH2 (1p12). Frequent findings of homozygous deletions on 9p21 and 10q23 confirmed the importance of CDKN2A and PTEN. Pair-wise comparisons revealed distinct sets of alterations, for example, mutually exclusive mutations in BRAF and NRAS, mutual mutations in BRAF and PTEN, concomitant chromosome 7 gain and 10 loss and concomitant chromosome 15q22.2-q26.3 gain and 20 gain. Moreover, alterations of the various melanoma genes were associated with distinct chromosomal imbalances suggestive of specific genomic programs in melanoma development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.